 One of the interesting things I saw in the earnings results and some of the commentary from management, we were just talking about the impact of the GLP-1 drugs. CEO Tim Wentworth noted they are losing money on the pharmacy-filling prescriptions for those GLP-1 drugs. So the impact of them being felt within their own industry in addition to some of the ancillary industries. Jason, anything to add on the Walgreens side?